ALArleen Li

Arleen Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Arleen Li has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Eligulashvili

    Department of Radiology, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America

    1 shared publication
  • David Joseph Altschul

    Department of Neurological Surgery and Montefiore-Einstein Cerebrovascular Research Lab, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    1 shared publication
  • Devaraju Kanmaniraja

    Department of Radiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

    1 shared publication
  • Ellen L. Wolf

    Department of Radiology, Montefiore Medical Center, Bronx, USA

    1 shared publication
  • Emad Eskandar

    Department of Neurological Surgery, Montefiore Health System and Albert Einstein College of Medicine, Bronx, New York, United States of America

    1 shared publication
  • Ilir Agalliu

    Department of Epidemiology and Population Health, Albert Einstein College of Medicine , Bronx, NY

    1 shared publication

Latest Publications

  • Open Access

    Lesion Volume Dynamics Add Prognostic Value Beyond Prostate Imaging Reporting and Data System Score Increase for Predicting Confirmatory Biopsy Upgrade During Active Surveillance

    by Theodoros Karanikolas, Jonah Tripp, Morgan Joseph, Arleen Li, Ilir Agalliu, Stephen Reese, Devaraju Kanmaniraja, Kara Watts

    Purpose: This study aimed to evaluate the association of Prostate Imaging Reporting and Data System (PIRADS) score increase and lesion volume progression on serial prostate magnetic resonance imaging (MRI) with confirmatory biopsy outcomes in a racially and ethnically diverse cohort of patients undergoing active surveillance for prostate cancer.Materials and Methods: We conducted a single-center retrospective cohort study of men with Gleason 3+3 and 3+4 prostate cancer managed with active surveillance at our institution from 2016 to 2025 who had diagnostic and confirmatory biopsies and corresponding prostate MRI examinations within prespecified windows of each biopsy. Biopsy-level, demographic, clinical, imaging, and treatment data were abstracted. Imaging progression was defined as any increase in maximum PI-RADS score or a ≥30% increase in maximum lesion volume (MLV). Outcomes included Gleason grade group (GG) upgrading and increased length of Gleason pattern 4 (GP4) on confirmatory biopsy. Multivariable logistic regression models adjusted for age, race/ethnicity, time between biopsies, prostate-specific antigen density, and GG at diagnosis were used to evaluate associations between imaging progression and upgrading. Receiver operating characteristic analysis was used to compare discriminative performance.Results: Among 160 patients (73% Black or Hispanic/Latino), 52 (32.5%) had upgrading at confirmatory biopsy. In separate multivariable models, both PI-RADS score increase (odds ratio [OR], 4.06; 95% confidence interval [CI], 1.77–9.76; p=0.001) and MLV increase ≥30% (OR, 4.29; 95% CI, 1.98–9.74; p<0.001) were independently associated with upgrading on confirmatory biopsy compared with no interval imaging change. On receiver operating characteristic analysis, MLV increase (area under the curve [AUC], 0.673) and combined PI-RADS score and MLV progression (AUC, 0.714) outperformed PI-RADS score increase alone (AUC, 0.619). Among patients with baseline GG2 disease, PI-RADS score increase was associated with increased GP4 burden from diagnostic-to-confirmatory biopsy.Conclusion: During early active surveillance, progression in MRI-derived tumor volume provided clinically meaningful prognostic information beyond PI-RADS score increase for predicting upgrading on confirmatory biopsy, including in a racially and ethnically diverse cohort. Incorporating MRI change metrics may help guide decision-making about confirmatory biopsy in active surveillance protocols.

  • Open Access

    Imaging approach to retroperitoneal vascular tumors: a narrative review

    by Arleen Li, Ellen L. Wolf, Shabnam Fidvi

    Primary retroperitoneal tumors are rare and can encompass a large range of pathologies, including both benign and malignant etiologies. Retroperitoneal tumors with a vascular component constitute a small percentage of these tumors, and include intravascular and extravascular leiomyosarcoma, paraganglioma, extrarenal angiomyolipoma, Castleman disease, angiosarcoma, hemangioma, cystic lymphangioma, and inflammatory myofibroblastic tumor. Cross-sectional imaging is often valuable to characterize vascular retroperitoneal masses and delineate their relationship with surrounding anatomical structures, aiding in surgical planning. This article aims to review the imaging features of these vascular retroperitoneal tumors and presents a diagnostic approach to aid in diagnosing these tumors.


  • Open Access

    Long-term outcomes of hospitalized patients with SARS-CoV-2/COVID-19 with and without neurological involvement: 3-year follow-up assessment

    by Anna Eligulashvili, Moshe Gordon, Jimmy S. Lee, Jeylin Lee, Shiv Mehrotra-Varma, Jai Mehrotra-Varma, Kevin Hsu, Imanyah Hilliard, Kristen Lee, Arleen Li, et al.

    Background: Acute neurological manifestation is a common complication of acute Coronavirus Disease 2019 (COVID-19) disease. This retrospective cohort study investigated the 3-year outcomes of patients with and without significant neurological manifestations during initial COVID-19 hospitalization. Methods and findings: Patients hospitalized for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection between 03/01/2020 and 4/16/2020 in the Montefiore Health System in the Bronx, an epicenter of the early pandemic, were included. Follow-up data was captured up to 01/23/2023 (3 years post-COVID-19). This cohort consisted of 414 patients with COVID-19 with significant neurological manifestations and 1,199 propensity-matched patients (for age and COVID-19 severity score) with COVID-19 without neurological manifestations. Neurological involvement during the acute phase included acute stroke, new or recrudescent seizures, anatomic brain lesions, presence of altered mentation with evidence for impaired cognition or arousal, and neuro-COVID-19 complex (headache, anosmia, ageusia, chemesthesis, vertigo, presyncope, paresthesias, cranial nerve abnormalities, ataxia, dysautonomia, and skeletal muscle injury with normal orientation and arousal signs). There were no significant group differences in female sex composition (44.93% versus 48.21%, p = 0.249), ICU and IMV status, white, not Hispanic (6.52% versus 7.84%, p = 0.380), and Hispanic (33.57% versus 38.20%, p = 0.093), except black non-Hispanic (42.51% versus 36.03%, p = 0.019). Primary outcomes were mortality, stroke, heart attack, major adverse cardiovascular events (MACE), reinfection, and hospital readmission post-discharge. Secondary outcomes were neuroimaging findings (hemorrhage, active and prior stroke, mass effect, microhemorrhages, white matter changes, microvascular disease (MVD), and volume loss). More patients in the neurological cohort were discharged to acute rehabilitation (10.39% versus 3.34%, p < 0.001) or skilled nursing facilities (35.75% versus 25.35%, p < 0.001) and fewer to home (50.24% versus 66.64%, p < 0.001) than matched controls. Incidence of readmission for any reason (65.70% versus 60.72%, p = 0.036), stroke (6.28% versus 2.34%, p < 0.001), and MACE (20.53% versus 16.51%, p = 0.032) was higher in the neurological cohort post-discharge. Per Kaplan–Meier univariate survival curve analysis, such patients in the neurological cohort were more likely to die post-discharge compared to controls (hazard ratio: 2.346, (95% confidence interval (CI) [1.586, 3.470]; p < 0.001)). Across both cohorts, the major causes of death post-discharge were heart disease (13.79% neurological, 15.38% control), sepsis (8.63%, 17.58%), influenza and pneumonia (13.79%, 9.89%), COVID-19 (10.34%, 7.69%), and acute respiratory distress syndrome (ARDS) (10.34%, 6.59%). Factors associated with mortality after leaving the hospital involved the neurological cohort (odds ratio (OR): 1.802 (95% CI [1.237, 2.608]; p = 0.002)), discharge disposition (OR: 1.508 (95% CI [1.276, 1.775]; p < 0.001)), congestive heart failure (OR: 2.281 (95% CI [1.429, 3.593]; p < 0.001)), higher COVID-19 severity score (OR: 1.177 (95% CI [1.062, 1.304]; p = 0.002)), and older age (OR: 1.027 (95% CI [1.010, 1.044]; p = 0.002)). There were no group differences in radiological findings, except that the neurological cohort showed significantly more age-adjusted brain volume loss (p = 0.045) than controls. The study’s patient cohort was limited to patients infected with COVID-19 during the first wave of the pandemic, when hospitals were overburdened, vaccines were not yet available, and treatments were limited. Patient profiles might differ when interrogating subsequent waves. Conclusions: Patients with COVID-19 with neurological manifestations had worse long-term outcomes compared to matched controls. These findings raise awareness and the need for closer monitoring and timely interventions for patients with COVID-19 with neurological manifestations, as their disease course involving initial neurological manifestations is associated with enhanced morbidity and mortality.


  • Open Access

    Imaging features of intra-abdominal and intra-pelvic causes of hirsutism

    by Arleen Li, Noah Bloomgarden, Shari Friedman, Milana Flusberg, Victoria Chernyak, Robert Berkenblit

    Hirsutism is a relatively common disorder which affects approximately 5% to 15% of women. It is defined by excessive growth of terminal hair in women, which primarily affects areas dependent on androgens, such as the face, abdomen, buttocks, and thighs. Hirsutism can be caused by a variety of etiologies, which are most often not lifethreatening. However, in some cases, hirsutism can be an indicator of more serious underlying pathology, such as a neoplasm, which may require further elucidation with imaging. Within the abdomen and pelvis, adrenal and ovarian pathologies are the primary consideration. The goal of this manuscript is to review the etiologies and imaging features of various intra-abdominal and intra-pelvic causes of hirsutism.